Comparing Treatments for Age-related Macular Degeneration: Safety, Effectiveness and Cost

Loading...
Thumbnail Image
Penn collection
Issue Briefs
Degree type
Discipline
Subject
evidence development & decision science
comparative effectiveness research/PCORI
Health Services Research
Funder
Grant number
Copyright date
Distributor
Author
Maguire, Maureen G
Contributor
Abstract

Comparative effectiveness research (CER) has received widespread attention and federal funding because of its potential to inform and improve treatment decisions. Since 2005, patients and their ophthalmologists have faced a dilemma in treating age-related macular degeneration (AMD)—the leading cause of blindness in the United States. Two closely related drugs have produced dramatic improvements in vision; one has been rigorously tested for use in AMD patients, while the other has been rigorously tested for use in cancer patients, but is now widely used to treat AMD. One drug costs 40 times as much as the other. This Issue Brief summarizes a CER study comparing these drugs head-to-head, and provides the most definitive evidence to date about the safety and effectiveness of the two alternatives.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2012-06-13
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection